EARNINGS AND TRADING: B90 "confident" for full year as revenue grows
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
| Price | 9.50p on 30-09-2026 at 18:15:06 |
|---|---|
| Change | 0.00p 0% |
| Buy | 10.00p |
| Sell | 9.00p |
| Last Trade: | Sell 4,433.00 at 9.11p |
| Day's Volume: | 9,535 |
| Last Close: | 9.50p |
| Open: | 9.50p |
| ISIN: | VGG042401262 |
| Day's Range | 9.50p - 9.50p |
| 52wk Range: | 8.75p - 18.25p |
| Market Capitalisation: | £7.52m |
| VWAP: | 9.408378p |
| Shares in Issue: | 79.19m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Crism Thera (CRTX) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 4,433 | 9.11p | Ordinary |
14:49:05 - 30-Sep-26 |
| Sell* | 9 | 9.00p | Ordinary |
13:25:45 - 30-Sep-26 |
| Sell* | 1,875 | 9.11p | Ordinary |
11:28:58 - 30-Sep-26 |
| Sell* | 18 | 9.00p | Ordinary |
10:01:13 - 30-Sep-26 |
| Buy* | 100 | 10.00p | SI Trade |
09:54:52 - 30-Sep-26 |
| Buy* | 100 | 10.00p | SI Trade |
09:54:52 - 30-Sep-26 |
| Buy* | 3,000 | 10.00p | Ordinary |
08:52:59 - 30-Sep-26 |
| Sell* | 4,760 | 9.11p | Ordinary |
15:31:39 - 29-Sep-26 |
| Sell* | 3,323 | 9.15p | Ordinary |
14:38:08 - 29-Sep-26 |
| Sell* | 10,000 | 9.01p | Ordinary |
09:03:17 - 29-Sep-26 |
Crism Thera (CRTX) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 21st Sep 2026 7:00 am | RNS | Interim Results |
| 17th Sep 2026 7:00 am | RNS | Appointment of Non-executive Chair |
| 20th Aug 2026 11:05 am | RNS | Commencement of Patient Recruitment |
| 13th Aug 2026 7:00 am | RNS | Clinical Trial Update |
| 29th Jul 2026 4:02 pm | RNS | Holding(s) in Company |
| 27th Jul 2026 7:00 am | RNS | Result of Shareholder Analysis |
| 2nd Jul 2026 4:31 pm | RNS | Holding(s) in Company |
| 30th Jun 2026 3:30 pm | RNS | Grant of Options |
| 26th Jun 2026 7:00 am | RNS | FINAL RESULTS |
| 25th Jun 2026 7:00 am | RNS | Phase 2 Clinical Trial Progress Update |